Clinical trials: Oral Phase
Measles-Mumps-Rubella
Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months
To evaluate the Immunogenicity and Safety of Shanghai Institute of Biological Products Co., Ltd.'s Measles, Mumps and Rubella (MMR) Vaccine Compared to a Licensed and WHO Prequalified GSK MMR Vaccine in Healthy African Children…
- Trial name
- NCT06399003
- Testing
- SIBP MMR Vaccine, GSK MMR Vaccine (PRIORIX), Yellow Fever Vaccine (Stamaril)
- Where
- Kenya
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Arteriosclerosis, Hypercholesterolaemia
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in participants with high cardiovascular risk.
- Trial name
- NCT06008756
- Testing
- Enlicitide Decanoate
- Where
- 669 sites in United States, Argentina and 27 more
- Volunteers
- 14,550 people
- Sponsor
- Merck Sharp & Dohme LLC
Disintegration, Healthy
Scintigraphy Study to Evaluate the Gastrointestinal Behavior of EDP1815 Oral Dosage Forms
This study is to find out how different types of capsules or tablets containing EDP1815 move through the GI tract and release the drug after being swallowed.
- Trial name
- NCT05066373
- Testing
- EDP1815 capsule A, EDP1815 capsule B, EDP1815 tablet
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Evelo Biosciences, Inc.
Breast Cancer, Metastatic Breast Cancer
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
The purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with FGF aberrant metastatic breast cancer, as well as in the treatment of patients with biomarker negative (FGF…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, MBC, HER2 Positive
- Trial name
- NCT02202746
- Testing
- Lucitanib
- Where
- 33 sites in United States
- Volunteers
- 178 people
- Sponsor
- Clovis Oncology, Inc.
Healthy
Evaluate the Effects of Food on the Pharmacokinetics of Fadanafil in Healthy Subjects
The purpose of this study is to evaluate the effect of high fat meal on the pharmacokinetics of single oral fadanafil tablet 100mg in healthy subjects. Fadanafil is a selective phosphodiesterase (PDE5) inhibitor.
- Trial name
- NCT04467203
- Testing
- Fadanafil
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
Liposarcoma
Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma
To determine the MTD/RP2D of the HDM201 and LEE011 combination and evaluate whether the combination is safe and has beneficial effects in patients with liposarcoma.
- Trial name
- NCT02343172
- Testing
- HDM201, LEE011
- Where
- 9 sites in Canada, France and 4 more
- Volunteers
- 74 people
- Sponsor
- Novartis Pharmaceuticals
Bioequivalence
Partially Replicate Bioequivalence Study of Quetiapine 25 mg in Healthy Volunteers Under Fasting Condition
The current study is conducted to evaluate and compare the relative bioavailability for Quetiapine in two different products containing 25 mg Quetiapine after a single oral dose administration under fasting conditions.
- Trial name
- NCT05235230
- Testing
- Test product (T) 25 mg Film Coated Tablets, Reference product (R) 25 mg Film Coated Tablets
- Where
- Egypt
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Future University in Egypt
Healthy Volunteer, HIV Vaccine
Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults
The purpose of this study is to test experimental human immunodeficiency virus (HIV) vaccines that use an adenovirus vector. The adenovirus vector may help the vaccines stimulate an immune response.
- Trial name
- NCT02771730
- Testing
- Ad4-mgag, Ad4-EnvC150, AIDSVAX B/E
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Cystic Fibrosis
Study of Ataluren (PTC124™) in Cystic Fibrosis
Cystic fibrosis (CF) is a genetic disorder caused by a mutation in the gene that makes the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
- Trial name
- NCT00803205
- Testing
- Ataluren
- Where
- 38 sites in United States, Belgium and 9 more
- Volunteers
- 238 people
- Sponsor
- PTC Therapeutics
Leukemias, Myelodysplastic Syndromes
Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes
The goal of this safety/pharmacology study is to determine MTD of sapacitabine when administered in patients with advanced leukemias or myelodysplastic syndromes.
- Trial name
- NCT00380653
- Testing
- sapacitabine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Obesity, Overweight
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.
- Trial name
- EVOLVE-2 (NCT07281937)
- Testing
- VRB-101
- Where
- 22 sites in United States
- Volunteers
- 206 people
- Sponsor
- Verdiva Bio Dev Limited
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
NATIENS: Optimal Management and Mechanisms of SJS/TEN
The North American Therapeutics in Epidermal Necrolysis Syndrome (NATIENS) study is a multicenter double-blind randomized controlled assessment of two arms - one of systemic immunomodulatory therapy (etanercept) and one of…
- Trial name
- NATIENS (NCT02987257)
- Testing
- Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4
- Where
- 14 sites in United States
- Volunteers
- 2 people
- Sponsor
- Vanderbilt University Medical Center
Gingivitis
Dose-Response Study of Iocide Oral Rinse
The purpose of this study is to explore the dose-response relationship of Iocide oral rinse in a clinical trial of gingivitis. Approximately sixty (60) otherwise healthy subjects having gingivitis will be randomized into the…
- Trial name
- NCT01103102
- Testing
- Iocide Oral Rinse
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Biomedical Development Corporation
Overweight or Obesity
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）
This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy and safety of the oral small molecule MDR-001 Tablets over 52 weeks as an adjunct to a lifestyle intervention…
- Trial name
- NCT07274137
- Testing
- MDR-001
- Where
- 45 sites in China
- Volunteers
- 738 people
- Sponsor
- MindRank AI Ltd
Advanced Solid Tumor, Liver Metastases
Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases
Single centre recruiting approximately 80 patients who are given a rising single, followed by multiple, ascending oral dose of AZD2171, assessing the safety and tolerability of AZD2171 in patients with solid tumors and metastatic…
- Trial name
- NCT00501605
- Testing
- AZD2171
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- AstraZeneca
Neoplasms
Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours
The primary objective of the study was to identify the maximum tolerated dose and to evaluate safety, pharmacokinetics, pharmacodynamic parameters, and efficacy of BIBW 2992.
- Trial name
- NCT02171702
- Testing
- BIBW 2992
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Dental Caries
Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects
The purpose of the clinical study is to evaluate the safety and bacterial impact of study drug (C16G2) administered in multiple oral gel doses to adolescent and adult dental subjects.
- Trial name
- NCT02509845
- Testing
- C16G2
- Where
- 5 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Armata Pharmaceuticals, Inc.
Solid Tumours
To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours
This is a 3-part study in patients with advanced solid tumours: Part A will assess the effect of itraconazole on the PK parameters of olaparib and will determine the effect of olaparib on the QT interval following single oral…
- Trial name
- NCT01900028
- Testing
- Pharmacokinetic sampling, Olaparib tablet dosing, Itraconazole
- Where
- 14 sites in Belgium, Denmark and 2 more
- Volunteers
- 85 people
- Sponsor
- AstraZeneca
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of TY-1091 in Patients With Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of TY-1091 administered orally in…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, Neoplasms
- Trial name
- NCT05675605
- Testing
- TY-1091
- Where
- China
- Volunteers
- 248 people
- Sponsor
- TYK Medicines, Inc
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in Healthy Subjects
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple repeat oral doses of PF-06372865 in healthy adult subjects.
- Trial name
- NCT03351751
- Testing
- PF-06372865
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.